Xerostomia Therapeutics Market to Grow with a CAGR of 3.75% through 2030

Increasing Aging Population and Increased Medication Use are expected to drive the Global Xerostomia Therapeutics Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Xerostomia Therapeutics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Xerostomia Therapeutics Market stood at USD 2.15 Billion in 2024 and is anticipated to grow with a CAGR of 3.75% in the forecast period, 2026-2030.

The global xerostomia therapeutics market is gaining strong momentum, underpinned by increasing clinical awareness, demographic shifts, and the evolving needs of a performance-oriented population. A key driver is the aging global population, with individuals over 65 increasingly affected by xerostomia due to both age-related physiological changes and the use of multiple medications that suppress salivary function. As this demographic expands, pharmaceutical companies and healthcare providers are prioritizing the development of targeted therapies, creating sustained demand for solutions specifically designed for older adults.

The widespread use of medications such as antihypertensives, antidepressants, antihistamines, and anticholinergics all of which commonly cause dry mouth has contributed significantly to the condition’s rising prevalence. Moreover, chronic illnesses like diabetes and Sjögren’s syndrome, which are tightly linked to xerostomia, are becoming more common globally. This convergence of medication side effects and chronic disease comorbidities has positioned xerostomia as a growing clinical priority, prompting the need for effective, long-term therapeutic strategies.

Beyond medical implications, xerostomia increasingly affects day-to-day functionality in high-paced environments. Individuals experiencing dry mouth often struggle with concentration, clear verbal communication, and maintaining adequate hydration and nutrition all of which are essential for sustained performance. In response, the market is seeing a surge in demand for user-friendly, fast-acting products such as lozenges, sprays, and saliva stimulants that support both clinical outcomes and daily productivity.

These therapeutics not only improve comfort but also deliver measurable functional benefits. They help users maintain cognitive focus, reduce interruptions caused by discomfort, and enhance verbal fluency in professional and social settings. Furthermore, by supporting better hydration and dietary intake, xerostomia products contribute to sustained energy levels and overall health. In workplace and academic environments, this translates to improved output and efficiency, making xerostomia therapeutics a practical wellness solution as much as a clinical intervention.

The xerostomia therapeutics market is transitioning from a symptom-focused niche to a broader, value-driven health category. Driven by demographic trends, increased chronic disease prevalence, and rising expectations for quality of life, the market presents a strong opportunity for innovation, strategic investment, and cross-sector collaboration in both pharmaceutical and consumer health landscapes.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Xerostomia Therapeutics Market”

The Global Xerostomia Therapeutics Market is segmented into type, product, regional distribution, and company

Based on its product, The Salivary Stimulants segment is projected to experience rapid growth during the forecast period. Salivary stimulants are specifically designed to address the underlying issue of reduced salivary gland function, which is a primary cause of xerostomia. They work by activating the salivary glands to produce more saliva, providing a direct solution to the problem. By targeting the root cause, salivary stimulants offer comprehensive relief from dry mouth symptoms. This approach not only alleviates discomfort but also helps maintain better oral health by supporting the natural lubrication and protective functions of saliva. Salivary stimulants are effective for a wide range of patients, including those who experience medication-induced xerostomia. Many prescription medications, such as antihypertensives and antidepressants, reduce salivary flow, and salivary stimulants can help counteract these effects. The global population is aging, and age-related xerostomia is prevalent due to reduced salivary gland function. Salivary stimulants are beneficial for elderly individuals, as they can help restore and maintain adequate saliva production, improving their oral health and quality of life. Salivary stimulants are particularly valuable for cancer patients who have undergone radiation therapy to the head and neck area. This treatment often damages the salivary glands, leading to chronic xerostomia. Salivary stimulants provide essential relief for these individuals, allowing them to manage their dry mouth symptoms effectively. Salivary stimulants are available in various forms, including lozenges, chewing gum, sprays, and oral tablets. This diversity allows patients to choose the administration method that best suits their preferences and needs. This variety increases patient compliance, as individuals are more likely to use treatments that align with their comfort and preferences. Salivary stimulants are typically non-invasive and well-tolerated by patients. They do not involve needles, complex procedures, or the introduction of potentially unpleasant substances. This non-invasive nature makes them appealing to a broad range of patients. These factors collectively contribute to the growth of this segment.

Based on region, The Asia-Pacific market is poised to be the fastest-growing market, offering lucrative growth opportunities for Xerostomia Therapeutics players during the forecast period. Factors such as Asia-Pacific region are experiencing a growing middle class with increased disposable income. This demographic shift leads to higher healthcare expenditure and greater willingness to seek treatment for health conditions, including xerostomia. The Asia-Pacific region has a significantly larger population compared to North America. With an aging population and an increased incidence of chronic diseases, there is a substantial pool of potential xerostomia patients, which fuels market growth. The region is witnessing increased healthcare awareness, and patients are becoming more informed about their health conditions and available treatment options. Infrastructure improvements and greater access to healthcare services, including dental care, are contributing to the diagnosis and management of xerostomia in the region.

Major companies operating in Global Xerostomia Therapeutics Market are:

• GlaxoSmithKline plc
• Church & Dwight Co., Inc.
• Colgate-Palmolive Company
• Hikma Pharmaceuticals PLC
• Pendopharm
• Sun Pharmaceuticals Industries Ltd
• Lupin Pharmaceuticals, Inc.
• Pfizer, Inc.
• Parnell Pharmaceuticals, Inc.
• Acacia Pharma

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The Technological Advancements and Product Innovation and increasing Awareness and Diagnosis are key drivers of the Xerostomia Therapeutics market. In recent years, the growing emphasis on patient well-being and the demand for personalized healthcare solutions drive the adoption of xerostomia therapeutics that improve patients' quality of life. Moreover, the growing consumer emphasis on preventative healthcare products has enhanced production and marketing efforts. To meet the demands of the market, manufacturers are increasingly incorporating cutting-edge technologies with high production efficiency. Rising consumer acceptance and continuous product innovation will further ensure the growth of the Xerostomia Therapeutics market in the coming years.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Xerostomia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Type (OTC, Prescription), By Product (Salivary Stimulants, Salivary Substitutes, Dentifrices), By Region, & Competition, 2020-2030F”, has evaluated the future growth potential of Global Xerostomia Therapeutics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Xerostomia Therapeutics Market.

Contact Us-

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

M: +13322586602

Email: sales@techsciresearch.com

Website: www.techsciresearch.com